Nune Markosyan

Nune Markosyan

Auto-generated profile, based on publicly available information

Nune Markosyan

Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SKSamantha B. Kemp
Samantha B. Kemp
NCNoah Cheng
Noah Cheng
NMNune Markosyan
Nune Markosyan
RSRina Sor
Rina Sor
IKIl-Kyu Kim
Il-Kyu Kim
BSBen Z. Stanger
Ben Z. Stanger
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies. Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247

7 March 2025 in Cancer Discovery
Verified
Journal Article
Open access
MOMargo Orlen
Margo Orlen
WVWilliam P. Vostrejs
William P. Vostrejs
RSRina Sor
Rina Sor
JMJayne C. McDevitt
Jayne C. McDevitt
SKSamantha B. Kemp
Samantha B. Kemp
BSBen Z. Stanger
Ben Z. Stanger
Activating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment, rendering PDAC tumors insensitive to immunotherapy. RAS(ON) multi-selective inhibitors, such as daraxonrasib (RMC-6236) and RMC-7977, target the active state of RAS, with potent antitumor activity in PDAC murine models. In this study, we report that RAS(ON) multi-selective inhibition led to rapid and profound PDAC regressions in immunocompetent mice, decreasing myeloid cells and increasing T cells and macrophages in the tumor microenvironment. The depth and duration of tumor regression depended on T cells and conventional dendritic cells. Moreover, the combination of RAS(ON) multi-selective inhibitors with immunotherapy conferred deeper and more durable tumor regressions, including complete responses not seen with either treatment alone. In summary, concurrent inhibition of mutant and wild-type RAS is active in concert with T-cell immunotherapy, revealing RAS(ON) multi-selective inhibitors as a potential therapeutic immuno-sensitizing strategy in PDAC. Significance: RAS(ON) multi-selective inhibitors enhance antitumor immunity in preclinical models of PDAC, resulting in deeper and more durable responses when combined with immunotherapy. These findings support the clinical evaluation of immune-based strategies that may prolong the response to RAS inhibitor therapies as well as overcome issues of therapeutic resistance to inhibitors alone. See related commentary by Lasse Opsahl and Pasca di Magliano, p. 1537

30 September 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
SKSamuel I. Kim
Samuel I. Kim
MHMargaret E. Haerr
Margaret E. Haerr
MAMaryam Al-Ghezi
Maryam Al-Ghezi
CCCanping Chen
Canping Chen
YZYi Zhang
Yi Zhang
KBKatelyn T. Byrne
Katelyn T. Byrne
Low or absent expression of MHC on tumor cells is a presumed mechanism of resistance to immunotherapy, but evidence for this has largely been indirect. Likewise, whether immunotherapy can be effective without tumor MHC expression is also poorly understood. Using genetically engineered mouse tumor cells expressing the model neoantigen ovalbumin, we found that MHC class I–deficient tumor cells, but not MHC class I–sufficient tumor cells, grew progressively when injected subcutaneously into syngeneic C57BL/6 mice. However, combination immunotherapy using agonistic anti-CD40 and dual immune checkpoint blockade (anti–PD-1 and anti–CTLA-4) was equally effective against tumors that did not express the MHC class I H-2Kb allele, MHC class II, or IFNγ receptor across multiple pancreatic tumor lines (regardless of ovalbumin). Moreover, CD4+ T cells, but not CD8+ T cells or perforin, were necessary to mediate immunotherapeutic responses. We excluded a role for CD4+ T cell–instructed macrophage-mediated tumor cell death but observed reprogramming of MHC class II–expressing stromal cells within the tumor after anti-CD40/ICB treatment. These data indicate that cancer immune surveillance by T cells does not absolutely require tumor-expressed MHC class I nor CD8+ T cells but instead can facilitate a clinically relevant remodeling of endothelial cells, further underscoring tumor-extrinsic roles for CD4+ T cells as mediators of tumor rejection and durable immune memory.

4 August 2025
Verified
Other
Open access
PDF file
MOMargo Orlen
Margo Orlen
WVWilliam P. Vostrejs
William P. Vostrejs
RSRina Sor
Rina Sor
JMJayne C. McDevitt
Jayne C. McDevitt
SKSamantha B. Kemp
Samantha B. Kemp
BSBen Z. Stanger
Ben Z. Stanger
Supplementary Figure S4: RAS(ON) multi-selective inhibition results in early changes to the PDAC tumor immune microenvironment

4 August 2025
Verified
Other
Open access
PDF file
MOMargo Orlen
Margo Orlen
WVWilliam P. Vostrejs
William P. Vostrejs
RSRina Sor
Rina Sor
JMJayne C. McDevitt
Jayne C. McDevitt
SKSamantha B. Kemp
Samantha B. Kemp
BSBen Z. Stanger
Ben Z. Stanger
Supplementary Figure S6: Effects of RAS(ON) multi-selective inhibition on T cell phenotypes in tumor-draining lymph nodes

4 August 2025
Verified
Other
Open access
PDF file
MOMargo Orlen
Margo Orlen
WVWilliam P. Vostrejs
William P. Vostrejs
RSRina Sor
Rina Sor
JMJayne C. McDevitt
Jayne C. McDevitt
SKSamantha B. Kemp
Samantha B. Kemp
BSBen Z. Stanger
Ben Z. Stanger
Supplementary Figure S9: Effect of combination anti-PD-1 and RAS(ON) multiselective inhibition on body weight, tumor growth, and survival